'Lipoproteins, glycoxidation and diabetic angiopathy'

被引:68
|
作者
Jenkins, AJ
Best, JD
Klein, RL
Lyons, TJ
机构
[1] Univ Melbourne, Dept Med, St Vincents Hosp, Fitzroy, Vic, Australia
[2] Med Univ S Carolina, Div Endocrinol Diabet Med Genet, Charleston, SC USA
[3] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Metab & Hypertens Sect, Oklahoma City, OK 73104 USA
关键词
lipoproteins; advanced glycation end-products; oxidation; diabetes; vascular disease;
D O I
10.1002/dmrr.491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chronic vascular complications of diabetes (nephropathy, retinopathy and accelerated atherosclerosis) are a major cause of morbidity and premature mortality. In spite of the more widespread availability of intensive diabetes management, approximately one in three people with diabetes develop aggressive complications and over 70% die of atherosclerosis-related diseases. Genetic and acquired factors are likely to be contributory. Potential mediators of vascular damage may include the interrelated processes of lipoprotein abnormalities, glycation, oxidation and endothelial dysfunction. Lipoprotein abnormalities encompass alterations in lipid concentrations, lipoprotein composition and subclass distribution and lipoprotein-related enzymes. Nonenzymatic glycation and oxidative damage to lipoproteins, other proteins and to vascular structures may also be deleterious. As atherosclerosis is a chronic condition commencing in youth, and because clinical events may be silent in diabetes, surrogate measures of vascular disease are important for early identification of diabetic patients with or at high risk of vascular damage, and for monitoring efficacy of interventions. The increasing array of biochemical assays for markers and mediators of vascular damage, noninvasive measures of vascular health, and therapeutic options should enable a reduction in the excessive personal and economic burden of vascular disease in type 1 and type 2 diabetes. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:349 / 368
页数:20
相关论文
共 50 条
  • [1] DIABETIC ANGIOPATHY - DIABETIC KIDNEY AND DIABETIC MACRO-ANGIOPATHY
    LUNDBAEK, K
    REVISTA CLINICA ESPANOLA, 1978, 148 (06): : 545 - 552
  • [2] Circulating oxidized low-density lipoproteins and antibody to oxidized low-density lipoproteins in Type 2 diabetic subjects: the role of glycoxidation
    Sartore, G
    Piarulli, F
    Lapolla, A
    Cantaro, S
    Reitano, R
    Fiore, C
    Marin, R
    Bassan, S
    Piconi, L
    Manzato, E
    Fedele, D
    DIABETOLOGIA, 2004, 47 : A412 - A412
  • [3] DIABETIC ANGIOPATHY
    LUNDBAEK, K
    ACTA DIABETOLOGICA LATINA, 1973, 10 (02): : 183 - 207
  • [4] DIABETIC ANGIOPATHY
    LUNDBAEK, K
    MODERN CONCEPTS OF CARDIOVASCULAR DISEASE, 1974, 43 (08) : 103 - 107
  • [5] DIABETIC ANGIOPATHY
    ROMANI, JD
    NOUVELLE PRESSE MEDICALE, 1972, 1 (20): : 1364 - &
  • [6] DIABETIC ANGIOPATHY
    SCHULZEBERGMANN, G
    ZENTRALBLATT FUR CHIRURGIE, 1978, 103 (12): : 805 - 810
  • [7] DIABETIC ANGIOPATHY
    BEAVEN, DW
    AUSTRALASIAN ANNALS OF MEDICINE, 1965, 14 (01): : 65 - +
  • [8] DIABETIC ANGIOPATHY
    SCHULZEBERGMANN, G
    THERAPIE DER GEGENWART, 1977, 116 (07): : 1282 - &
  • [9] THROMBOSIS AND DIABETIC ANGIOPATHY
    DUPUY, E
    GUILLAUSSEAU, PJ
    LUBETZKI, J
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1982, 24 (03): : 173 - 177
  • [10] Diabetic angiopathy in children
    Danne, T
    Kordonouri, O
    Hovener, G
    Weber, B
    DIABETIC MEDICINE, 1997, 14 (12) : 1012 - 1025